Article
15 Jul 2025
2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law
AUTHORS CONTENT
Article
09 Jul 2025
Finalized PMPRB Guidelines Published
Article
30 Jun 2025
Update On Biosimilars In Canada – June 2025
Article
25 Jun 2025
Health Canada Consultation On Revised Biosimilar Guidance: No Requirement For Comparative Clinical Efficacy And Safety Trials
Article
07 Jan 2025
2024 Highlights In Canadian Life Sciences IP And Regulatory Law
Article
30 Dec 2024
Agile Licensing Amendments Registered
Article
30 Dec 2024
PMPRB Releases New Draft Guidelines For Comment
Article
02 Oct 2024
PM(NOC) Regulations: Seven-year Anniversary Of Major Amendments
Article
30 Aug 2024
Manitoba Last Province To Introduce Biosimilars Initiative, While Ontario Adds Four Drugs To Its Biosimilar Policy
Article
12 Jul 2024
2024 Mid-Year Highlights In Canadian Life Sciences IP And Regulatory Law
Article
01 Apr 2024
Update On Biosimilars In Canada – March 2024
Article
26 Jan 2024
Federal Court Finds PMPRB Reasonably Concluded Galderma's Patent Claiming 0.3% Adapalene "Pertained To" 0.1% Adapalene DIFFERIN
Article
15 Jan 2024
2023 Highlights in Canadian Life Sciences IP and Regulatory Law
Article
02 Jan 2024
Government Of Canada Announces Creation Of Canadian Drug Agency
Article
20 Nov 2023
PMPRB Publishes Scoping Paper For Consultation On Guidelines And Invites Stakeholder Feedback
Article
31 Oct 2023
PMPRB News: Upcoming Roundtable As First Phase Of New Guidelines Consultation, Two New Appointments
Article
26 Sep 2023
PM(NOC) Regulations: Six-Year Anniversary Of Major Amendments
Article
01 Aug 2023
Developments In Time-Limited Pharmaceutical Market Access: PCPA Temporary Access Process
Article
07 Jul 2023
2023 Mid-Year Highlights In Canadian Life Sciences IP And Regulatory Law
Article
03 Jul 2023
Updates From CADTH: Improvements To CADTH Reimbursement Review Process, Increased Fees And New Formulary Management Expert Committee Pilot
AWARDS
